Development and validation of a 6-plex Luminex-based assay for measuring human serum antibodies to group B streptococcus capsular polysaccharides

References

• Verani JR, McGee L, Schrag SJ. Prevention of perinatal group B streptococcal disease–revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010 Nov 19;59(RR–10):1–12.
   PubMedGoogle Scholar
• Johri AK, Lata H, Yadav P, Dua M, Yang Y, Xu X, Homma A, Barocchi MA, Bottomley MJ, Saul A, et al. Epidemiology of group B streptococcus in developing countries. Vaccine. 2013 Aug 28;31(Suppl 4):D43–5. doi: 10.1016/j.vaccine.2013.05.094.
   PubMedGoogle Scholar
• Le Doare K, Heath PT. An overview of global GBS epidemiology. Vaccine. 2013 Aug 28;31(Suppl 4):D7–12. doi:10.1016/j.vaccine.2013.01.009.
   PubMedGoogle Scholar
• Bolukaoto JY, Monyama CM, Chukwu MO, Lekala SM, Nchabeleng M, Maloba MRB, Mavenyengwa RT, Lebelo SL, Monokoane ST, Tshepuwane C, et al. Antibiotic resistance of streptococcus agalactiae isolated from pregnant women in Garankuwa, South Africa. BMC Res Notes. 2015 Aug 20;8:364. doi:10.1186/s13104-015-1328-0.
   PubMedGoogle Scholar
• Cheng Z, Qu P, Ke P, Yang X, Zhou Q, Lan K, He M, Cao N, Qin S, Huang X, et al. Antibiotic resistance and molecular epidemiological characteristics of streptococcus agalactiae isolated from pregnant women in Guangzhou, South China. Can J Infect Dis Med Microbiol. 2020;2020:1–11. doi:10.1155/2020/1368942.
   Web of Science ®Google Scholar
• Preventing neonatal group B streptococcal infection. Intrapartum antibiotic prophylaxis in some high-risk situations. Prescrire Int. 2011 Mar;20(114):72–7.
   PubMedGoogle Scholar
• Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine. 2013 Aug 28;31(Suppl 4):D20–6. doi:10.1016/j.vaccine.2012.11.056.
   PubMedGoogle Scholar
• Jordan HT, Farley MM, Craig A, Mohle-Boetani J, Harrison LH, Petit S, Lynfield R, Thomas A, Zansky S, Gershman K, et al. Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease: a multistate, population-based analysis. Pediatr Infect Dis J. 2008 Dec;27(12):1057–64. doi:10.1097/INF.0b013e318180b3b9.
   PubMed Web of Science ®Google Scholar
• Marques MB, Kasper DL, Pangburn MK, Wessels MR. Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun. 1992 Oct;60(10):3986–93. doi:10.1128/iai.60.10.3986-3993.1992.
   PubMed Web of Science ®Google Scholar
• Absalon J, Segall N, Block SL, Center KJ, Scully IL, Giardina PC, Peterson J, Watson WJ, Gruber WC, Jansen KU, et al. Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial. Lancet Infect Dis. 2021 Feb;21(2):263–274. doi:10.1016/S1473-3099(20)30478-3.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Anderson AS, Absalon J, Radley D, Simon R, Jongihlati B, Strehlau R, van Niekerk AM, Izu A, Naidoo N, et al. Potential for maternally administered vaccine for infant group B streptococcus. N Engl J Med. 2023 Jul 20;389(3):215–227. doi: 10.1056/NEJMoa2116045.
   PubMed Web of Science ®Google Scholar
• Madrid L, Seale AC, Kohli-Lynch M, Edmond KM, Lawn JE, Heath PT, Madhi SA, Baker CJ, Bartlett L, Cutland C, et al. Infant group B streptococcal disease incidence and serotypes worldwide: systematic review and meta-analyses. Clin Infect Dis. 2017 Nov 6;65(suppl_2):S160–S172. doi: 10.1093/cid/cix656.
   PubMedGoogle Scholar
• Absalon J, Simon R, Radley D, Giardina PC, Koury K, Jansen KU, Anderson AS. Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches. Hum Vaccin Immunother. 2022 Dec 31;18(1):2037350. doi:10.1080/21645515.2022.2037350.
   PubMed Web of Science ®Google Scholar
• Vekemans J, Crofts J, Baker CJ, Goldblatt D, Heath PT, Madhi SA, Le Doare K, Andrews N, Pollard AJ, Saha SK, et al. The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations. Vaccine. 2019 May 27;37(24):3190–3198. doi: 10.1016/j.vaccine.2019.04.039.
   PubMed Web of Science ®Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine. 2005 Mar 18;23(17–18):2222–7. doi:10.1016/j.vaccine.2005.01.051.
   PubMed Web of Science ®Google Scholar
• Jodar L, Butler J, Carlone G, Dagan R, Goldblatt D, Käyhty H, Klugman K, Plikaytis B, Siber G, Kohberger R, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine. 2003 Jul 4;21(23):3265–72. doi: 10.1016/S0264-410X(03)00230-5.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Carey VJ, Rench MA, Edwards MS, Hillier SL, Kasper DL, Platt R. Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis. 2014 Mar 1;209(5):781–8. doi:10.1093/infdis/jit549.
   PubMed Web of Science ®Google Scholar
• Dangor Z, Kwatra G, Izu A, Khan M, Lala SG, Madhi SA. Infant serotype specific anti-capsular immunoglobulin G antibody and risk of invasive group B Streptococcal disease. Vaccine. 2021 Nov 16;39(47):6813–6. doi:10.1016/j.vaccine.2021.10.022.
   PubMed Web of Science ®Google Scholar
• Dangor Z, Kwatra G, Izu A, Adrian P, Cutland CL, Velaphi S, Ballot D, Reubenson G, Zell ER, Lala SG, et al. Correlates of protection of serotype-specific capsular antibody and invasive group B streptococcus disease in South African infants. Vaccine. 2015 Nov 27;33(48):6793–9. doi: 10.1016/j.vaccine.2015.10.019.
   PubMed Web of Science ®Google Scholar
• Lin FY, Weisman LE, Azimi PH, Philips III J, Clark P, Regan J, Rhoads G, Frasch C, Gray B, Troendle J, et al. Level of maternal IgG anti–group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis. 2004 Sep 1;190(5):928–34. doi: 10.1086/422756.
   PubMed Web of Science ®Google Scholar
• Lin FY, Philips JB 3rd, Azimi PH, Weisman L, Clark P, Rhoads G, Regan J, Concepcion N, Frasch C, Troendle J, et al. Level of maternal antibody required to protect neonates against early-onset disease caused by group B streptococcus type ia: a multicenter, seroepidemiology study. J Infect Dis. 2001 Oct 15;184(8):1022–8. doi: 10.1086/323350.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Izu A, Kwatra G, Jones S, Dangor Z, Wadula J, Moultrie A, Adam Y, Pu W, Henry O, et al. Association of group B streptococcus (GBS) serum serotype-specific anticapsular immunoglobulin G concentration and risk reduction for invasive GBS disease in South African infants: an observational birth-cohort, matched case-control study. Clin Infect Dis. 2021 Sep 7;73(5):e1170–e1180. doi: 10.1093/cid/ciaa1873.
   PubMed Web of Science ®Google Scholar
• Fabbrini M, Rigat F, Rinaudo CD, Passalaqua I, Khacheh S, Creti R, Baldassarri L, Carboni F, Anderloni G, Rosini R, et al. The protective value of maternal group B streptococcus antibodies: quantitative and functional analysis of naturally acquired responses to capsular polysaccharides and pilus proteins in European maternal sera. Clin Infect Dis. 2016 Sep 15;63(6):746–753. doi: 10.1093/cid/ciw377.
   PubMed Web of Science ®Google Scholar
• Dangor Z, Kwatra G, Izu A, Lala SG, Madhi SA. Review on the association of group B streptococcus capsular antibody and protection against invasive disease in infants. Expert Rev Vaccines. 2015 Jan;14(1):135–49. doi:10.1586/14760584.2014.953939.
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Isbrucker R, Andrews N, Goldblatt D, Heath PT, Izu A, Madhi SA, Moulton L, Schrag SJ, Shang N, et al. Methodology for a correlate of protection for group B streptococcus: report from the bill & melinda gates foundation workshop held on 10 and 11 February 2021. Vaccine. 2022 Jul 30;40(32):4283–4291. doi: 10.1016/j.vaccine.2022.05.016.
   PubMed Web of Science ®Google Scholar
• Le Doare K, Kampmann B, Vekemans J, Heath PT, Goldblatt D, Nahm MH, Baker C, Edwards MS, Kwatra G, Andrews N, et al. Serocorrelates of protection against infant group B streptococcus disease. Lancet Infect Dis. 2019 May;19(5):e162–e171. doi:10.1016/S1473-3099(18)30659-5.
   PubMed Web of Science ®Google Scholar
• Esadze A, Grube CD, Wellnitz S, Singh S, Nguyen HH, Gaylord MA, Zhu A, Gribenko A, Tan CY, Anderson AS, et al. Calibration of a serum reference standard for group B streptococcal polysaccharide conjugate vaccine development using surface plasmon resonance. NPJ Vaccines. 2023 May 19;8(1):71. doi: 10.1038/s41541-023-00667-1.
   PubMed Web of Science ®Google Scholar
• Buurman ET, Timofeyeva Y, Gu J, Kim J-H, Kodali S, Liu Y, Mininni T, Moghazeh S, Pavliakova D, Singer C, et al. A novel hexavalent capsular polysaccharide conjugate vaccine (GBS6) for the prevention of neonatal group B streptococcal infections by maternal immunization. J Infect Dis. 2019 Jun 5;220(1):105–115. doi: 10.1093/infdis/jiz062.
   PubMed Web of Science ®Google Scholar
• Kumar M, Turner S. Protocol: a medium-throughput method for determination of cellulose content from single stem pieces of Arabidopsis thaliana. Plant Methods. 2015;11(1):46. doi:10.1186/s13007-015-0090-6.
   PubMedGoogle Scholar
• Sashidhar RB, Capoor AK, Ramana D. Quantitation of epsilon-amino group using amino acids as reference standards by trinitrobenzene sulfonic acid. A simple spectrophotometric method for the estimation of hapten to carrier protein ratio. J Immunol Methods. 1994 Jan 3;167(1–2):121–7. doi:10.1016/0022-1759(94)90081-7.
   PubMed Web of Science ®Google Scholar
• Park WJ, Yoon YK, Kim Y, Park J-S, Pansuriya R, Cho S-N, Seok Y-J, Ganapathy R. Development of a bivalent conjugate vaccine candidate against rotaviral diarrhea and tuberculosis using polysaccharide from Mycobacterium tuberculosis conjugated to ΔVP8* protein from rotavirus. Vaccine. 2021 Oct 29;39(45):6644–52. doi:10.1016/j.vaccine.2021.09.067.
   PubMed Web of Science ®Google Scholar
• Pavliakova D, Giardina PC, Moghazeh S, Sebastian S, Koster M, Pavliak V, McKeen A, French R, Jansen KU, Pride M, et al. Development and validation of 13-plex Luminex-based assay for measuring human serum antibodies to streptococcus pneumoniae capsular polysaccharides. mSphere. 2018 Aug 8;3(4). doi:10.1128/mSphere.00128-18.
   Web of Science ®Google Scholar
• Pickering JW, Hill HR. Measurement of antibodies to pneumococcal polysaccharides with Luminex xMAP microsphere-based liquid arrays. Methods Mol Biol. 2012;808:361–75.
   PubMedGoogle Scholar
• FDA. Bioanalytical method validation guidance for industry. Washington, DC: Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM); 2018.
   Google Scholar
• ICH HTG, editor. Validation of analytical procedures: text and methodology, Q2 (R1). Current step 4 version, parent guidelines on methodology dated November 6 1996. Incorporated in November 2005. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland; 2005.
   Google Scholar
• Reinsch CH. Smoothing by spline functions. Numer Math. 1967;10(3):177–&. doi:10.1007/BF02162161.
   Web of Science ®Google Scholar
• GASTON. Group B streptococcus: standardization of laboratory assays. London, United Kingdom: St George’s, University of London; 2019 [accessed 2021 Mar 17].https://www.gbsatstgeorges.co.uk/_files/ugd/cb083f_54c3427d57094e4082e79a7e27b9ec91.pdf.
   Google Scholar
• Buffi G, Galletti B, Stella M, Proietti D, Balducci E, Romano MR, Mori E, Fabbrini M, Giuliani MM, Berti F, et al. Novel multiplex immunoassays for quantification of IgG against group B streptococcus capsular polysaccharides in human sera. mSphere. 2019 Aug 7;4(4). doi:10.1128/mSphere.00273-19.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med. 1976 Apr 1;294(14):753–6. doi:10.1056/NEJM197604012941404.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Kasper DL, Tager I, Paredes A, Alpert S, McCormack WM, Goroff D. Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B streptococcus. J Clin Invest. 1977 May;59(5):810–8. doi:10.1172/JCI108703.
   PubMed Web of Science ®Google Scholar
• Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, Benjamin W, Quataert SA, Hildreth S, Sikkema DJ, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003 Jul;10(4):514–9. doi:10.1128/CDLI.10.4.514-519.2003.
   PubMedGoogle Scholar
• WHO. WHO preferred product characteristics for group B streptococcus vaccines. Geneva, Switzerland: World Health Organization; 2017.
   Google Scholar
• Le Doare K, Gaylord MA, Anderson AS, Andrews N, Baker CJ, Bolcen S, Felek A, Giardina PC, Grube CD, Hall T, et al. Interlaboratory comparison of a multiplex immunoassay that measures human serum IgG antibodies against six group B streptococcus polysaccharides. Hum Vaccin Immunother. 2024. doi:10.1080/21645515.2024.2330138.
   PubMedGoogle Scholar